Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 8 Jan 2024 |
| 87 000 Orion Corporation A shares converted into B shares | 4 Dec 2023 |
| Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database | 21 Nov 2023 |
| Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution) | 20 Nov 2023 |
| Orion Corporation: Managers' transactions - Agendum Oy | 16 Nov 2023 |
| Orion Corporation: Managers' transactions - Mikael Silvennoinen | 16 Nov 2023 |